Back to today’s briefing

Story perspectives

UK Approves Seladelpar for Primary Biliary Cholangitis Treatment

1/17/2025

32 7

Summary

Story summary

On January 16, 2025, the UK's MHRA granted approval for seladelpar (Livdelzi) to treat Primary Biliary Cholangitis (PBC) in adults. This new treatment can be combined with ursodeoxycholic acid (UDCA) for patients who don't respond to it or used alone for those who can't tolerate it. Ongoing safety monitoring will ensure patient well-being.

1 of 1

Story summary

On January 16, 2025, the UK's MHRA granted approval for seladelpar (Livdelzi) to treat Primary Biliary Cholangitis (PBC) in adults. This new treatment can be combined with ursodeoxycholic acid (UDCA) for patients who don't respond to it or used alone for those who can't tolerate it. Ongoing safety monitoring will ensure patient well-being.